Mollecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer
Authors:
P. Fabian; J. Berkovcová
Authors place of work:
Oddělení onkologické a experimentální patologie, Masarykův onkologický ústav, Brno
Published in the journal:
Čes.-slov. Patol., 47, 2011, No. 4, p. 154-158
Category:
Reviews Article
Summary
The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth factor receptor are effective in approximately 10% and 20% of EGFR expressing, chemotherapy resistant metastatic colorectal cancer patients in monotherapy and in combination with chemotherapy, respectively. The evidence that EGFR expression by immunohistochemistry does not predict clinical outcome in EGFR targeted treatment has led to an intensive search for additional predicitive biomarkers. Oncogenic activation of signalling pathways downstream of the EGFR, such as mutation of KRAS, BRAF, or PIK3CA oncogenes, or inactivation of the PTEN tumor supressor gene is central to the progression of colorectal cancer. Tumor KRAS mutation, which may be present in 35%–45% of patients with colorectal cancer, is now recognized as an important predictive marker of resistance to cetuximab or panitumumab treatment and is also widely used in clinical practice. Among tumors carrying wild-type KRAS, mutations of BRAF or PIK3CA or loss of PTEN expression may be associated with resistance to the anti-EGFR monoclonal antibody treatment. On the other hand, EGFR ligands overexpression detected in tumor tissue is a promising positive predictive marker. There are also some initial observations that gene expression profiling could also contribute to clinical decision-making about the cetuximab and panitumumab treatments. These observations require further validation in prospective clinical trials before incorporation into clinical practice.
Keywords:
EGFR – targeted therapy – prediction – colorectal carcinoma
Zdroje
1. Dušek L, Abrahámová J, Mužík, J et al. Populační odhady počtu nemocných s kolorektálním karcinomem – jeden z nástrojů včasné diagnostiky časných stadií a rekurence onemocnění. Farmakoterapie 2009; 5: 11–20.
2. www.svod.cz
3. Poston GJ, Figueras J, Giuliante F et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26(29): 4828–4833.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337–345.
5. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22(7): 1201–1208.
6. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patiens with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23(9): 1803–1810.
7. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancor. J Clin Oncol 2007; 25(13): 1658–1664.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2(2): 127–137.
9. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fl uoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(14): 2311–2319.
10. Němeček R, Kocáková I, Kocák I, et al. Cetuximab a irinotecan v léčbě metastatického kolorektálního karcinomu – pilotní výsledky Masarykova onkologického ústavu. Klin Onkol 2009; 22(1): 27–33.
11. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626–1634.
12. De Rookck W, Piessevaux H, De Schutter J, et al. KRAS wildtype state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19(3): 508–515.
13. Lievre A, Bachet JB, Le CD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66(8): 3992–3995.
14. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3): 374–379.
15. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 663–671.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17): 1757–1765.
17. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27(35): 5931–5937.
18. Wellcome Trust Sanger Institute. Catalogue of somatic mutations in cancer.
http://www.sanger.ac.uk/genetics/CG
/cosmic/. Accessed April 15, 2011.
19. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49(17): 4682–4689.
20. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67(6): 2643–2648.
21. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360(6): 563–572.
22. Dubská L, Vyskočilová M, Nenutil R et al. Vyšetření mutačního stavu genu KRAS jako součást algoritmu léčby metastatického kolorektálního karcinomu. Cas Lek Ces 2011; 150(6): 321–326.
23. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9(10): 962–972.
24. Saridaki Z, Georgoulias V, Souglakos J et al. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.World J Gastroenterol 2010; 16(10): 1177–1187.
25. Di NF, Martini M, Molinari F, et al. Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26(35): 5705–5712.
26. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27(35): 5924–5930.
27. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69(5): 1851–1857.
28. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101(3): 465–472.
29. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418 (6901): 934.
30. Fearon ER, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell 1990; 61(5): 759–767.
31. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26(35): 5705–5712.
32. Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome. Br J Cancer 2010; 102(12): 1762–1768.
33. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68(6): 1953–1961.
34. Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27(9): 1477–1484.
35. Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15(9): 3184–3188.
36. De Rook W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11(8): 753–762.
37. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22(18): 2812–2822.
38. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27(16): 2622–2629.
39. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancor patients. Br J Cancer 2007; 97(8): 1139–1145.
40. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20(1): 84–90.
41. Razis E, Briasoulis E, Vrettou E, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer. An exploratory study. BMC Cancer 2008; 8: 234.
42. Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplifi cation in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005; 18(10): 1350–1356.
43. Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer patients with low or negative tumor epidermal growth factor receptor levels: an updated analysis J Clin Oncol 2007; 25(18): 4082.
44. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal rowth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6(5): 279–286.
45. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25(22): 3238–3245.
46. Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancor patients. Ann Oncol 2008; 19(4): 717–723.
47. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patiens treated with cetuximab: a fl uorescent in situ hybridization study. Clin Cancer Res 2008; 14(18): 5869–5876.
48. Al-Kuraya K, Novotny H, Bavi P, et al. HER2, TOP2A, CCND1, EGFR and C- MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007; 60(7): 768–72.
49. Petrova D, Jankova R, Yosifova A, et al. Tissue microarray analysis of EGFR gene amplification and gain in Bulgarian patients with colorectal cancer. Onkologie 2006; 29 (5): 198–200.
50. Goncalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008; 8: 169.
51. Wang WS, Chen PM, Chiou TJ, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res 2007; 13(12): 3597–3604.
52. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351(27): 2883.
53. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25(22): 3230–3237.
54. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27(30): 5068–5074.
55. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009; 13(9): 145.
56. Baker JB, Dutta D, Watson D et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011; 104(3): 488–495.
57. Bardelli A, Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28(7): 1254-1261.
58. Siena S, Sartore-Bianchi A, Di Nicolantonio F. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101(19): 1308-24.
59. Spindler KL, Pallisgaard N, Lindebjerg J, Frifeldt SK, Jakobsen A. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. J BMC Cancer 2011; 11: 107.
60. Park JH, Han SW, Oh DY. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol. In press 2011.
61. Saridaki Z, Tzardi M, Papadaki C et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011; 6(1): e15980.
Štítky
Anatomical pathology Forensic medical examiner ToxicologyČlánok vyšiel v časopise
Czecho-Slovak Pathology
2011 Číslo 4
Najčítanejšie v tomto čísle
- Carney complex
- Predictive diagnosis of HER2 in gastric adenocarcinoma
- Giant cutaneous basal cell carcinoma of the head with intracranial propagation – a case report
- Acatholytic Variant of Squamous Carcinoma of the Breast. A Case Report and Review of Literature